Cost-effectiveness of patient selection using penumbral-based mri for intravenous thrombolysis

Stroke

Volumn 40, Issue 5, 2009, Pages 1710-1720

  Earnshaw, Stephanie R ^a   Jackson, Dan ^b   Farkouh, Ray ^a   Schwamm, Lee ^c  

^a RTI HEALTH SOLUTIONS   (United States)

^b GE HEALTHCARE   (United Kingdom)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cost effectiveness analysis; Economics; Ischemic stroke; MRI; Stroke management

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR; FIBRINOLYTIC AGENT;

ARTICLE; BLOOD CLOT LYSIS; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; STROKE; AGED; ALGORITHM; BRAIN HEMORRHAGE; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; ECONOMICS; FEMALE; FIBRINOLYTIC THERAPY; IMAGE PROCESSING; INTRAVENOUS DRUG ADMINISTRATION; MALE; PATHOLOGY; PATIENT SELECTION; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME;

AGED; ALGORITHMS; CEREBRAL HEMORRHAGE; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; INFUSIONS, INTRAVENOUS; MAGNETIC RESONANCE IMAGING; MALE; PATIENT SELECTION; PROPORTIONAL HAZARDS MODELS; QUALITY-ADJUSTED LIFE YEARS; STROKE; THROMBOLYTIC THERAPY; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 65549156923     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.108.540138     Document Type: Article

References (44)

1. Centers for Disease Control and Prevention (CDC). Prevalence of disabilities and associated health conditions among adults: United States, 1999. MMWR Morb Mortal Wkly Rep. 2001;50:120-125.
2. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, Hailpern SM, Ho M, Howard V, Kissela B, Kittner S, Lloyd-Jones D, McDermott M, Meigs J, Moy C, Nichol G, O'Donnell C, Roger V, Sorlie P, Stein-berger J, Thom T, Wilson M, Hong Y, for the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007;115;e69-e171.
3. Adams HP Jr, Adams RJ, Brott T, del Zoppo GJ, Furlan A, Goldstein LB, Grubb RL, Higashida R, Kidwell C, Kwiatkowski TG, Marler JR, Hademenos GJ. Guidelines for the early management of patients with ischemic stroke: a scientific statement from the Stroke Council of the American Stroke Association. Stroke. 2003;34:1056-1083.
4. Reeves MJ, Arora S, Broderick JP, Frankel M, Heinrich JP, Hicken-bottom S, Karp H, LaBresh KA, Malarcher A, Mensah G, Moomaw CJ, Schwamm L, Weiss P; Paul Coverdell Prototype Registries Writing Group. Acute stroke care in the US: results from 4 pilot prototypes of the Paul Coverdell National Acute Stroke Registry. Stroke. 2005;36: 1232-1240.
5. Activase [product label]. Genentech, Inc; 2005. Available at: http:// www.gene.com/gene/products/information/pdf/activase-prescribing.pdf. Accessed June 30, 2008.
6. Evenson KR, Rosamond WD, Morris DL. Pre-hospital and in-hospital delays in acute stroke care. Neuroepidemiology. 2001;20:65-76.
7. Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology. 2001;56:1015-1020.
8. Fiebach JB, Schellinger PD, Gass A, Kucinski T, Siebler M, Villringer A, Olkers P, Hirsch JG, Heiland S, Wilde P, Jansen O, Rother J, Hacke W, Sartor K. Stroke magnetic resonance imaging is accurate in hyperacute intracerebral hemorrhage. A multicenter study on the validity of stroke imaging. Stroke. 2004;35:502-507.
9. Fiebach JB, Schellinger PD, Jansen O, Meyer M, Wilde P, Bender J, Schramm P, Juttler E, Ohler J, Hartmann M, Hahnel S, Knauth M, Hacke W, Sartor K. CT and diffusion-weighted MR-imaging in randomized order: DWI results in higher accuracy and lower interrater variability in the diagnosis of hyperacute ischemic stroke. Stroke. 2002;33:2206-2210.
10. Chalela JA, Kidwell C, Nentwich L, Luby M, Butman J, Demchuk AM, Hill MD, Patronas N, Latour LL, Warach S. Magnetic resonance imaging and computed tomography in emergency assessment of patients with suspected acute stroke: a prospective comparison. Lancet. 2007;369: 293-398.
11. Schellinger PD, Fiebach JB, Hacke W. Imaging-based decision making in thrombolytic therapy for ischemic stroke: present status. Stroke. 2003;34: 575-583.
12. Schellinger PD, Thomalla G, Fiehler J, Kohrmann M, Molina CA, Neumann-Haefelin T, Ribo M, Singer OC, Zaro-Weber O, Sobesky J. MRI-based and CT-based thrombolytic therapy in acute stroke within and beyond established time windows: an analysis of 1210 patients. Stroke. 2007;38:2640-2645.
13. Rother J, Schellinger PD, Gass A, Siebler M, Villringer A, Fiebach JB, Fiehler J, Jansen O, Kucinski T, Schoder V, Szabo K, Junge-Hulsing GJ, Hennerici M, Zeumer H, Sartor K, Weiller C, Hacke W. Effect of intravenous thrombolysis on MRI parameters and functional outcome in acute stroke 6h. Stroke. 2002;33:2438-2445.
14. Hacke W, Albers G, Al-Rawi Y, Bogousslavsky J, Davalos A, Eliasziw M, Fischer M, Furlan A, Kaste M, Lees KR, Soehngen M, Warach S. The Desmoteplase in Acute Ischemic Stroke trial (DIAS): a Phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke. 2005;36:66-73.
15. Furlan AJ, Eyding D, Albers GW, Al-Rawi Y, Lees KR, Rowley HA, Sachara C, Soehngen M, Warach S, Hacke W. Dose Escalation of Des-moteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke. 2006;37:1227-1231.
16. Thomalla G, Schwark C, Sobesky J, Bluhmki E, Fiebach JB, Fiehler J, Zaro Weber O, Kucinski T, Juettler E, Ringleb PA, Zeumer H, Weiller C, Hacke W, Schellinger PD, Rother J. Outcome and symptomatic bleeding complications of intravenous thrombolysis within 6 hours in MRI-selected stroke patients: comparison of a German multicenter study with the pooled data of ATLANTIS, ECASS, and NINDS tPA trials. Stroke. 2006;37:852-858.
17. Kohrmann M, Juttler E, Fiebach JB, Huttner HB, Siebert S, Schwark C, Ringleb PA, Schellinger PD, Hacke W. MRI versus CT-based thrombolysis treatment within and beyond the 3 h time window after stroke onset: a cohort study. Lancet Neurol. 2006;5:661-667.
18. Albers GW, Thijs VN, Wechsler L, Kemp S, Schlaug G, Skalabrin E, Bammer R, Kakuda W, Lansberg MG, Shuaib A, Coplin W, Hamilton S, Moseley M, Marks MP. Magnetic resonance imaging profiles predict clinical response to early reperfusion: the Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution (DEFUSE) study. Ann Neurol. 2006;60:508-517.
19. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, Brott T, Frankel M, Grotta JC, Haley EC Jr, Kwiatkowski T, Levine SR, Lewandowski C, Lu M, Lyden P, Marler JR, Patel S, Tilley BC, Albers G, Bluhmki E, Wilhelm M, Hamilton S, the ATLANTIS Trials Investigators, ECASS Trials Investigators, NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363:768-774.
20. Fagan SC, Morgenstern LB, Petitta A, Ward RE, Tilley BC, Marler JR, Levine SR, Broderick JP, Kwiatkowski TG, Frankel M, Brott TG, Walker MD. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rtPA Stroke Study Group. Neurology. 1998;50:883-890.
21. Samsa GP, Reutter RA, Parmigiani G, Ancukiewicz M, Abrahamse P, Lipscomb J, Matchar DB. Performing cost-effectiveness analysis by integrating randomized trial data with a comprehensive decision model: application to treatment of acute ischemic stroke. J Clin Epidemiol. 1999;52:259-271.
22. Gold MR, Siegel JE, Russell LB, Weisten MC. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
23. Darby DG, Barber PA, Gerraty RP, Desmond PM, Yang Q, Parsons M, Li T, Tress BM, Davis SM. Pathophysiological topography of acute ischemia by combined diffusion-weighted and perfusion MRI. Stroke. 1999;30:2043-2052.
24. Morris DL, Rosamond W, Madden K, Schultz C, Hamilton S. Prehospital and emergency department delays after acute stroke. The Genentech Stroke Presentation Survey. Stroke. 2000;31:2585-2590.
25. Smith RW, Scott PA, Grant RJ, Chudnofsky CR, Frederiksen SM. Emergency physician treatment of acute stroke with recombinant tissue plasminogen activator: a retrospective analysis. Acad Emerg Med. 1999; 6:618-625.
26. Katzan IL, Hammer MD, Hixson ED, Furlan AJ, Abou-Chebl A, Nadzam DM. Cleveland Clinic Health System Stroke Quality Improvement Team: utilization of intravenous tissue plasminogen activator for acute ischemic stroke. Arch Neurol. 2004;61:346-350.
27. Kidwell CS, Alger JR, Saver JL. Beyond mismatch: evolving paradigms in imaging the ischemic penumbra with multimodal magnetic resonance imaging. Stroke. 2003;34:2729-2735.
28. Current Procedural Terminology cpt 2007. 2007. Chicago, IL: American Medical Association.
29. Ingenix, Inc. The essential RBRVS: a comprehensive listing of RBRVS values for CPT and HCPCS codes. Utah: Ingenix, Inc; 2006.
30. Red Book for Windows [computer program]. Version 61127, Volume 41. Montvale, NJ: Thomson PDR; July 2006.
31. Kleindorfer D, Hill MD, Woo D, Tomsick T, Pancioli A, Kissela B, Demchuk AM, Losiewicz D, Jauch E, Schneider A, Ringer A, Kanter D, Broderick JP. A description of Canadian and United States physician reimbursement for thrombolytic therapy administration in acute ischemic stroke. Stroke. 2005;36:682-687.
32. Reed SD, Blough DK, Meyer K, Jarvik JG. Inpatient costs, length of stay, and mortality for cerebrovascular events in community hospitals. Neurology. 2001;57:305-314.
33. Caro JJ, Huybrechts KF. Stroke Treatment Economic Model (STEM): predicting long-term costs from functional status. Stroke. 1999;30: 2574-2579.
34. Earnshaw SR, Joshi AV, Wilson MR, Rosand J. Cost-effectiveness of recombinant activated factor VII in the treatment of intracerebral hemorrhage. Stroke. 2006;37:2751-2758.
35. Chambers MG, Koch P, Hutton J. Development of a decision-analytic model of stroke care in the United States and Europe. Value Health. 2002;5:82-97.
36. Stahl JE, Furie KL, Gleason S, Gazelle GS. Stroke: effect of implementing an evaluation and treatment protocol compliant with NINDS recommendations. Radiology. 2003;228:659-668.
37. Gage BF, Cardinalli AB, Owens DK. Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation. Stroke. 1998;29:1083-1091.
38. Medical Consumer Price Index (MCPI). 2008. Available at: http:// data.bls.gov/PDQ/outside.jsp?survey=cu. Accessed June 30, 2008.
39. Arias E. United States life tables, 2003. Nat Vital Stat Rep. 2006;53.
40. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics. 2000;17:479-500.
41. Elhers L, Andersen G, Clausen LB, Bech M, Kjolby M. Cost-effectiveness of intravenous thrombolysis with alteplase within a 3-hour window after acute ischemic stroke. Stroke. 2007;38:85-89.
42. Davis SM, Donnan GA, Parsons MW, Levi C, Butcher KS, Peeters A, Barber PA, Bladin C, DeSilva DA, Byrnes G, Chalk JB, Fink JN, Kimber TE, Schultz D, Hand PJ, Frayne J, Hankey G, Muir K, Gerraty R, Tress BM, Desmond PM, for the EPITHET investigators. Effects of alteplase beyond 3 h after stroke in the Echoplanar imaging thrombolytic evaluation trial (EPITHET): a placebo-controlled randomized trial. Lancet Neurol. 2008;7:299-309.
43. Kane I, Sandercock P, Wardlaw J. Magnetic resonance perfusion diffusion mismatch and thrombolysis in acte ischaemic stroke: a systematic review of the evidence to date. JNeurol NeurosurgPsychiatry. 2007;78:485-491.
44. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgern N, Toni D, for the ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329.